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ABSTRACT
AXON INITIAL SEGMENT STABILITY IN MULTIPLE SCLEROSIS
By Suneel Krishna Thummala M.B.B.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Master
of Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2015.
Thesis Advisor: Jeffrey L. Dupree, Ph.D.
Associate Professor of Anatomy and Neurobiology

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system
characterized by inflammation and demyelination. In addition to these hallmark
features, MS also presents with axonal pathology, which is likely responsible for the
signs and symptoms of the disease. Although prominent in MS, axonal pathology is
frequently considered a consequence of demyelination and not a primary event.
This conclusion is consistent with demyelination inducing the loss of specific axonal
domains, known as the nodes of Ranvier that are responsible for the propagation of
action potentials along the axon. In contrast, we propose that axonal pathology
associated with MS is also independent of demyelination, and not a product of it. In
support of our hypothesis, we have analyzed a different axonal domain known as
the axon initial segment. Whereas a single axon has numerous nodes of Ranvier
uniformly distributed along the axon, each axon contains only a single axon initial
segment that is positioned immediately distal to the neuronal cell body. The axon
initial segment is responsible for action potential generation and modulation, and
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hence is essential for normal neuronal function. Background studies conducted by
our lab, employing a murine model of demyelination/remyelination, revealed no
correlation between axon initial segment stability and myelin integrity. Here we
investigate the fate of the axon initial segment in human multiple sclerosis. While
not statistically significant, we provide data demonstrating an apparent 40%
reduction in AIS numbers in MS. These findings are, however, highly preliminary
due to the limited number of samples. We further provide qualitative evidence that
AIS disruption in MS is not dependent on demyelination suggestive that axonal
pathology may be a primary event in MS. Our current findings are intriguing, but
unfortunately this study is underpowered, and more samples will be required to
determine whether this apparent reduction is statistically significant.

x

INTRODUCTION

Multiple sclerosis is a pervasive, debilitating disease of the central nervous system.
In the early 19 th century, Charcot first described the ‘sclerotic plaques’ from which
the disease eventually got its name (Charcot, 1868; as reviewed in Kornek and
Lassmann, 1999). These plaques are the histopathological hallmark feature of this
prototype demyelinating disease, characterized by the presence of well
circumscribed, multifocal inflammatory demyelinated lesions distributed over time
and space within the CNS (Files, 2015; Haines, 2012; Grigoriadisa, 2004). MS affects
approximately 400,000 individuals in the United States and affects 2.5 million
individuals worldwide (World Health Organization, 2008). Despite being clinically
silent for a large portion of its process, MS eventually presents with non-specific
cognitive symptoms such as sensory disturbances, ophthalmoplegia, parasthesias,
neuralgias, ataxia and/or neurogenic bowel and bladder symptoms (Noseworthy,
2000; Files, 2015). As the disease advances, patients undergo progressive cognitive
and/or psychiatric decline, having life expectancies shortened by 5-10 years,
attributable to increased risk of complications from neurological disability
(Compston and Coles, 2008). While studies have demonstrated a strong correlation
between this progressive neurological impairment and neurodegenerative
pathology, this process is traditionally considered to be a consequence of
demyelination (Hauser and Oksenberg, 2006). It has recently been proposed that
axonal pathology in MS could be a primary event in the disease process (Trapp et al.,
1998; Trapp and Nave, 2008; Haines et al., 2011). This project aims to explore this
1

concept, specifically investigating the susceptibility of a particular axonal domain,
the axon initial segment (AIS) to the multiple sclerosis disease process.

The Neuron:
Neurons are the specialized cell types of the central and peripheral nervous
systems. They are polarized cells, responsible for intercellular communication
through electrical or chemical signaling within the nervous system and to target
organs. Neurons are structurally and functionally composed of 3 distinct parts: the
dendrites, the cell body and the axon. Together the dendrites and the cell body
constitute the somatodendritic region. Dendrites are short membranous processes
exhibiting a tapered morphology, responsible for the reception and integration of
electrical and/or chemical synaptic inputs from neurons and other cells (Kevenaar
and Hoogenrad, 2015). The axon is the thin, long projection from the neuronal cell
body that transmits the signal to the receptors of subsequent neurons or other cells,
in the form of an electrical wave called the action potential (Stiess and Bradke,
2011). The axon is composed of specialized regions, such as: the axon hillock, axon
initial segment, nodes of Ranvier and the axon terminal, each playing a vital role in
this process. The axon hillock bridges the soma and the axon, and is the site where
inhibitory and excitatory synaptic inputs summate. The region adjacent to the axon
hillock is the axon initial segment, a highly specialized domain, composed unique
structural proteins and ion channels that allow for the generation and modulation of
an action potential (Clark et al., 2009; Buffington and Rasband, 2011). The nodes
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Figure 1. Schematic representation of a neuron. The chief components of a
typical CNS neuron highlighting the cell body (soma) and the axon, and their
various subparts. An oligodendrocyte and its contributing myelin sheath are also
observable. The axonal domains, the nodes of Ranvier and the axon initial
segment are labelled.
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of Ranvier (NoR) are short regions of the axon that lack a myelin sheath (the
insulating membrane that wraps around the axon). Both the myelin sheath as well
as the NoRs function in action potential propagation along the axon, ending in the
axon terminal, where the impulse is transmitted to target cells/organs through the
synapse, via electrical or chemical signals (Susuki and Rasband, 2008)

Myelin:
The term ‘myelin’, first coined by Rudolf Virchow in 1864, is used to describe the
lipid dense extension of the plasma membrane of oligodendrocytes (in the CNS) and
Schwann cells (in the PNS), which surrounds the axon, forming an insulating sheath
(Raine, 1984; Snaidero and Simons, 2014; Boulanger and Messier, 2014; Alizadeh et
al., 2015). By insulating the axon, and clustering sodium channels into the nodes of
Ranvier, myelin reduces the transverse capacitance and increases the transverse
resistance of the axonal plasma membrane, crucial for saltatory nerve conduction,
the basis of rapid information processing and communication between networks of
nerve cells in the CNS (Aggarwal et al., 2011; Nave and Werner., 2014; Hartline and
Colman, 2007). Oligodendrocytes, the myelin-forming cells of the CNS, extend their
plasma membranes in concentric loops, each process contacting and enveloping a
segment of the axon, forming a multi-layered sheath (Tomassy et al., 2015). In
addition to myelin generation, oligodendrocytes secrete metabolic factors that are
essential for the survival and integrity of CNS neurons (Tomassy et al., 2015;
Chamberlain et al., 2015; Edgar et al., 2009; Fünfschilling et al., 2012; Lee et al.,
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2012; Oluich et al., 2012). Maintenance and repair of the myelin sheath occurs
throughout adult life and includes spontaneous remyelination of neurons by
oligodendrocytes and their precursors (Irvine and Blakemore, 2008; Jeffery and
Blakemore, 1997; Kornek et al., 2000).
With an unusually high lipid concentration compared to other biological
membranes, myelin is composed of 30% protein and 70% lipid, a configuration that
is essential to myelin’s insulating property and function (Aggarwal et al., 2011) The
abundance of cholesterol, which constitutes 24-28% of total myelin lipids, likely
restricts membrane fluidity and carving affecting intercellular trafficking (Jahn et al.,
2009). Cholesterol is also the rate-limiting step in the formation of myelin, as
demonstrated by experiments conducted using Zebrafish, lacking the enzyme for
cholesterol synthesis (Mathews et al. 2014; Saher et al. 2005, 2009) Other lipids of
note are galactolipids, galactosylceramide (GalC), its sulfated form 3-Osulfogalactosylceramide (SGalC), and their hydroxylated forms GalC-OH and SGalCOH, which together add up to 20–26% of total myelin lipids (Bosio et al., 1998).
These lipids play crucial roles in interactions between the oligodendrocyte and the
axon, as well as maintenance of myelination (Coetzee et al., 1996; Dupree et at.,
1998; Bosio et al., 1998). Plasmalogens are a class of phospholipids that make up
12-15% of the total myelin lipid. Plasmalogens have an anti-oxidant effect, and
decreased levels have been implicated in demyelination in X-linked
adrenoleukodystrophy (Khan et al., 2008).
Of the principal protein components of CNS myelin, proteolipid protein (PLP)
and its smaller splice isoform, DM20, are the most prominent, making up 30-45% of

6

myelin protein. PLP plays a role in the formation of the intraperiod line, however,
despite their abundance, these proteins do not appear to play a vital role in the
establishment or maintenance of myelin, as studies using PLP/DM20 knockout mice
revealed periodicity issues, but did not show wide spread demyelination (Klugmann
et al., 1997; Coetzee et al., 1999)
Myelin basic protein (MBP) is the second most abundant myelin protein,
comprising up to 22–35% of total myelin protein. MBP plays a crucial role in myelin
compaction and stabilizing the major dense line, and absence of MBP results in
severe hypomyelination, as seen in the mouse mutant shiverer and the rat mutant
long evans shaker (Roach et al., 1985; O’Connor et al., 1999).
Other proteins of interest include 2′:3′-Cyclic nucleotide-3′phosphodiesterase (CNP), myelin-associated glycoprotein (MAG) and myelinoligodendrocyte protein (MOG). CNP is a major component of non-compact myelin,
and is associated with oligodendrocyte processes and paranodal loops and is said to
play a role in the cytoskeletal network of myelin (DeAngelis and Braun, 1996). MAG
functions in facilitating adhesion and signaling, between oligodendrocytes and
axons, during myelin formation (Quarles et al., 1992; Quarles and Morell, 1999).
MOG functions in transmitting extracellular information to the interior of
oligodendrocytes (Quarles et al., 2006). It is of particular interest to us because it is
the antigen that, when injected into an animal, elicits a cellular immune response
that produces the CNS autoimmune disease experimental autoimmune
encephalomyelitis (EAE).
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Axonal Domains:
Myelinated axons show a high degree of structural and functional organization, and
can be separated into several distinct, specialized domains; the node of Ranvier
(NoR), the paranode, the juxtaparanode, the internode and the axon initial segment
(AIS). These domains have similarities and differences with regards to structural
protein composition, function, and mechanisms of establishment and maintenance.
While they each play important roles in proper neuronal functioning, for the
purposes of this thesis, we will focus on the node of Ranvier and the axon initial
segment.

Nodes of Ranvier:
The nodes of Ranvier are myelin-bare regions of the axon spanning approximately
1- 2 μm in length (Peters et al., 1991; Salzer, 1997). The constricted diameter of the
node of Ranvier results in slowed axonal transport and therefore, higher densities of
vesicles, microtubules, mitochondria, and tightly packed neurofilaments (Fabricius
et al., 1993; Peters et al., 1991; Salzer, 1997). Vital for its role in action potential
propagation, the node contains a high concentration of voltage gated sodium
channels (Nav), including isotypes; Nav 1.1, Nav 1.2 and Nav 1.6 (Arancibia‐
Carcamo and Attwell, 2014; Buttermore et al., 2013; Thaxton and Bhat, 2009; Salzer,
1997). These sodium channels are anchored to the cytoskeleton through interaction,
at either its α- or β- subunits, with the scaffolding protein ankyrinG (ankG) (Bennett
and Lambert, 1999; Buttermore et al., 2013; Thaxton and Bhat, 2009). AnkG
associates with the spectrin- actin cytoskeleton through interactions with βIV8

spectrin, which is exclusively localized in the node and axon initial segment (Berghs
et al. 2000; Buttermore et al., 2013; Komada and Soriano, 2002). The node of
Ranvier also contains extracellular matrix molecules, cell adhesion molecules and
certain types of potassium channels.
Saltatory conduction is the process by which action potentials ‘jump’ across
unexcitable portions of the axon (myelin segments) from one node to the next . This
process is made possible by the high density clustering of sodium channels at the
nodes of Ranvier where ion flow occurs exclusively after the impulse has left the AIS
(Salzer, 2003; Sherman and Brophy, 2005). Ion channel clustering, as well as its
interactions with the ankyrinG and βIV-spectrin/actin network, at the node of
Ranvier is, therefore, vital for efficient action potential transmission (Bennett and
Lambert, 1999; Buttermore et al., 2013; Thaxton and Bhat, 2009). AnkyrinG,
described as the master regulator of AIS and NoR assembly (He et al., 2013; Kordeli
et al., 1995; Jenkins and Bennett, 2001; Sobotzik et al., 2009; Hedstrom et al., 2008;
Dzhashiashvili et al., 2007; Zhou et al. 1998), is responsible for the clustering of Nav
channels at the NoR. Sodium channels are anchored to the actin-cytoskeleton
through direct interaction with the scaffolding protein ankyrinG and indirect
interaction through adapter protein βIV-spectrin (Rasband, 2010; Eshed-Eisenbach
and Peles, 2013). Establishment of these interactions is critical for nodal clustering,
as mice lacking these stabilizing cytoskeletal associated proteins (ankG and/or βIVspectrin) display severely reduced sodium channel density (Gasser et al., 2012;
Komada and Soriano, 2002; Yang et al., 2004). Additionally, not only is ankyrinG
required for the establishment of the node of Ranvier, but it is also critical for
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maintaining the nodal protein complexes; as knock down of ankG results in cluster
dismantling (Hedstrom et al., 2008).
While myelin contact at the paranode is required for node of Ranvier
formation it is also vital for nodal maintenance. Studies conducted by our lab and
others show that compromised myelin-axon interactions result in a disruption of
nodal protein domain organization (Eshed-Eisenbach and Peles, 2013; Susuki et al.,
2013; Dupree et al., 1999). The Cuprizone model (discussed in detail later) is a
demyelinating murine model, in which myelin-forming oligodendrocytes are killed,
resulting in a complete loss of both nodally clustered sodium channels, as well as
paranodal clusters of caspr (Dupree et al., 2004).

Axon Initial Segment:
The axon initial segment (AIS) is an unmyelinated region of the axon, spanning
about 35-45 μm distally from the soma, located between the axon hillock and the
first myelin segment, in myelinated neurons. (Bender and Trussell, 2012; Grubb and
Burone, 2010; Rasband, 2010). The AIS serves as the site for action potential
initiation and modulation, as well as a gatekeeper between the somatodendritic and
axonal domains (Meeks et al., 2007; Rasband, 2010). Because the AIS and the node
of Ranvier both play roles in action potential transmission, their protein clusters are
very similar in composition (Rasband, 2010).
The axon initial segment serves as the action potential trigger zone due to its
high density of voltage-gated sodium channels. The AIS integrates signals from the
somatodendritic region of the neuron, and acts as an action potential threshold
10

“decision maker” (Inan et al., 2013; Kole and Stuart, 2012; Tai et al., 2014;
Yosihmura and Rasband, 2014). Action potential amplitude, duration and frequency
are thought to be regulated by the diversity of potassium channel subtypes (Kv1.2,
Kv2.2 and Kv7.2) present in the AIS (Kole et al., 2007; Sánchez-Ponce et al., 2012).
The AIS also undergoes frequent plasticity, such as changes in ion channel
localization and expression, alterations in AIS length, and physical relocation of the
AIS; all due, in part to synaptic input and pruning; thus fine-tuning neuronal
excitability (Adachi et al., 2014; Grubb and Burrone; Kaphzan et al., 2011; Kuba et
al., 2010,2012).
In addition to its role in action potential initiation and modulation, the axon
initial segment serves as a barrier between the somatodendritic and axonal
domains; thus maintaining neuronal polarity (Rasband, 2010). The mechanism
underlying this barrier is not fully understood, but it is hypothesized that the vast
number of AIS proteins could act as a sieve to weed out larger cytoplasmic
molecules (Nakada et al., 2003; Rasband, 2010).
The axon initial segment, like the node, contains a high density of voltage
gated sodium channels (Nav 1.1, Nav 1.2 and Nav 1.6); about 40-50 times that of the
somatodendritic domains (Rasband, 2010; Kole et al., 2008). Unlike the node, which
assists in the propagation of action potentials, these AIS Na+ channel clusters serve
as the trigger zone (Meeks et al., 2007). Similar to the node, the AIS is composed of a
variety of ion channels, cell adhesion molecules, extracellular matrix molecules and
cytoskeletal scaffolds. The master organizer molecule ankyrinG is responsible for
the interaction of these sodium channels to the axonal cytoskeleton and
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Figure 2. Axon initial segment and its constituent proteins. Ion channels, cell
adhesion molecules, neurotransmitter receptors and cytoskeletal proteins are
enriched at the AIS. AnkyrinG, dubbed the ‘master organizer’ of the AIS binds β4
spectrin and Nav channels.
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maintenance of neuronal polarity. Additionally, ankG silencing and its removal from
the mature AIS results in dismantling of the AIS, as detected through dispersion of
sodium channel, βIV-spectrin, NF-186, and NrCAM immunolabeling (Hedstrom et al.,
2008). AnkG is therefore, not only required for the initial recruitment and clustering
of AIS proteins, but also for the long-term maintenance of this domain. Recently, the
first human mutations in ankG were reported and shown to be associated with
severe intellectual disability, attention deficit hyperactivity disorder, and autism
(Iqbal et al., 2013).
Although the node of Ranvier and the AIS contain very similar protein
clusters, they are established and maintained through different processes, the most
noteworthy being their relationship with myelin. While both the formation and
maintenance of the node of Ranvier requires myelin contact, the AIS is formed
intrinsically through ankG restriction to the proximal end of the developing axon,
completely independent of myelination (Bennett and Baines, 2001; Galiano et al.,
2012). Data regarding the maintenance of the AIS with relation to myelin, is
however limited. Preliminary studies show that myelin may not be required to
preserve AIS integrity (Clark et al., [in review]; Hamada and Kole, 2015).

Multiple Sclerosis:
Multiple sclerosis (MS) is a debilitating neurological disease, characterized by the
immune mediated destruction of the myelin sheath, with subsequent neurological
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damage (Compston and Coles, 2002). MS is the leading cause of neurological
disability in young adults, and currently affects over 400,000 people in the United
States, and over 2.5 million people worldwide (Hauser and Oksenberg, 2006;
Noseworthy, 1999; Noseworthy et al., 2000; Trapp and Nave, 2008; Weinshenker,
1998). MS shows a peculiar worldwide distribution, with increased prevalence in
populations progressively further away from the equator. MS also
disproportionately affects females more than males, at a ratio of ~3:1 (Ahlgren et al.
2011; Compston and Coles, 2002; Orton et al. 2010; Wallin et al. 2012). MS is a
highly variable disease, believed to arise from a combination of genetic interactions
and environmental influences, but little is truly known about its cause or the factors
contributing to its unpredictable course and outcome (Compston and Coles, 2008)
Multiple sclerosis may follow one of four clinical courses based on disease activity
and progression: clinically isolated syndrome (CIS), relapsing-remitting multiple
sclerosis (RRMS), primary progressive multiple sclerosis (PPMS), and secondary
progressive multiple sclerosis (SPMS) (Lublin et al., 2014).
Clinically isolated syndrome (CIS) presents as a single isolated attack,
characterized by symptoms compatible with MS, but has yet to fulfill MS diagnostic
criteria. These patients may or may not progress to full blown MS (Miller et al.,
2012). Approximately 85 to 90 percent of affected adults develop relapsingremitting multiple sclerosis (RRMS) at onset, with a clinical course characterized by
intermittent attacks of increased disability followed by either partial or complete
recovery to their baseline function (Simone et al., 2002; Gusev et al., 2002; Banwell
et al., 2007; Renoux et al., 2007; Boiko et al., 2002). RRMS may evolve to secondary
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progressive multiple sclerosis (SPMS) in individuals who eventually show
progressive neurological decline without acute attacks or periods of remission.
Primary progressive multiple sclerosis (PPMS), a disease type characterized by
continuous disability over time in the absence of specific attacks, is much less
common than RRMS. A PPMS course is associated with the most rapid disease
progression and has the poorest prognostic value (Weinshenker, 1994; Tremlett et
at., 2006).

Pathogenesis:
Multiple sclerosis is thought to be attributable to an autoreactive attack on myelin
and oligodendrocytes by cells of the immune system that have entered the brain
and/or spinal cord, manifesting as acute focal inflammatory demyelination and
axonal loss with limited remyelination, culminating in the chronic multifocal
sclerotic plaques from which the disease gets its name. (Trapp and Nave, 2008) To
better understand the characteristic pathology of MS, we will tease apart and
examine each aspect individually.

MS Inflammation:
Inflammation in MS is believed to be mediated by a coordinated attack by T
lymphocytes and macrophages, against CNS tissue (Boppana et al., 2011). T cells
cross the blood brain barrier to enter the CNS. Activation of autoimmune responses
against myelin components in the CNS is hypothesized to occur through a variety of
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mechanisms such as molecular mimicry, bystander activation and epitope spreading
(Trapp and Nave, 2008; Popescu and Lucchinetti, 2012; Vanderlugt and Miller,
2002; von Herrath et al., 2003). As lymphocytes secrete matrix metalloproteinases
(MMP) to break down the blood brain barrier (BBB), the activated, autoreactive T
lymphocytes in the periphery, attach themselves to the receptors of endothelial
cells, granting them access through the BBB and into the central nervous system
(Compston and Coles, 2002, Hauser and Oksenberg, 2006). Once inside CNS
parenchyma, the T cells, reactivated by CNS myelin, stimulate pro-inflammatory
cytokines, such as TNF- α (Peterson and Fujinami, 2007; Hauser and Oksenberg,
2006), which stimulate the resident microglia and recruit B cells, astrocytes and
macrophages. Microglia secrete a host of factors such as TNFα (Haji et al., 2012),
iNOS (Starossom et al., 2012), IL-1β, COX2 and generate reactive oxygen species
(Guemez-Gamboa et al., 2011; Block et al., 2007) setting up a pro-inflammatory
loop. This combination of events creates an environment in which the hallmark
pathological processes of multiple sclerosis: demyelination and neuronal damage,
occur.

MS Demyelination:
The pathologic hallmark of MS consists of areas of focal demyelination, known as
plaques, characterized by reactive glial scar formation, inflammation, and partial
axonal sparing (Kutzelnigg and Lassmann, 2014). Both humoral and cell mediated
immune mechanisms play roles in the formation of these demyelinated lesions. As
described earlier, autoreactive T cells are responsible for the propagation of a highly
17

inflammatory environment, bind to MHC class I antigens on oligodendrocytes to
cause cell injury or they may produce demyelination through the endogenous
production of inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and
interferon-γ (INF-γ) (Noseworthy, 1999). Additionally, T cells drive the activation
and recruitment of microglia and macrophages, both key players in the initial and
sustained immune response to myelin antigens. Apart from secreting a variety of
cytotoxic and inflammatory factors, microglia can directly contact the myelin sheath
and oligodendrocytes, delivering lethal signals through surface bound TNFα (Zajicek
et al., 1992; Compston and Coles, 2002).
B cell activation and production of antibodies play a critical role in the
development of demyelination. Antibodies to myelin antigens such as myelin basic
protein (MBP) and myelin oligodendrocyte protein (MOG) have been detected in MS
plaques (Genain et al., 1999; O'Connor et al., 2005; O’Connor et al., 2007). Studies
show that novel targets to non-myelin antigens such as KIR4.1, neurofascin and
SPAG-16 mediate demyelination and axonal disruption (Fraussen et al., 2014; Levin
et al., 2013).
Demyelinated plaques in MS can be observed in both the white matter, as
well as cortical and subcortical gray matter (Brück 2005; Calabrese 2015). Plaques
are graded based on macrophage activity within the lesion. Acute active plaques are
characterized by massive infiltration of myelin-laden macrophages, with relative
axonal preservation and variable loss of oligodendrocytes (Brück et al., 1995;
Kutzelnigg and Lassmann, 2014; Popescu and Lucchinetti, 2012). Other
demyelinated lesions of interest are, chronic active plaques: regions of peripheral
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macrophage activity with hypocellular, gliotic centers; inactive plaques: completely
demyelinated, hypocellular lesions; and shadow plaques: sharply circumscribed,
light myelin staining regions representing areas of partial remyelination (Popescu
and Lucchinetti, 2012; Sobel and Moore, 2008; Prineas et al., 2001; Lucchinetti and
Bruck, 2004).

MS Neurodegeneration:
While multiple sclerosis has historically been considered a prototype demyelinating
disease, neuronal pathology plays an integral role in the functional pathogenesis of
MS. Charcot’s findings, describing substantial axonal damage in active lesions
(Kornek and Lassmann, 1999), were largely ignored until more recent landmark
papers revealed abundant transected and dystrophic axons in sites of active
inflammation and demyelination, and confirmed that partial or total axonal
transection begins early in the disease process (Bitsch et al., 2000, Ferguson et al.,
1997 and Trapp et al., 1998). Various pathological studies have demonstrated
reduced axonal density and in active, chronic and inactive plaques (DeLuca et al.,
2004; Bjartmar et al., 2000; Bitsch et al., 2000; Frischer et al., 2009). Accumulation
of amyloid precursor protein (APP) within the axon is caused by disruption of APP
transport down the axon, and is evidence of compromised axonal structure
integrity. APP accumulations have been observed in MS, within active lesions and
chronic plaques (Lovas et al., 2000; Mews et al., 1998; Ferguson et al., 1997). Axonal
pathology is further evidenced by magnetic resonance imaging (MRI) techniques,
visualizing whole brain atrophy (Miller et al., 2002), worsening focal (T1) lesions
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(Bagnato et al., 2003), disruption of white matter tracts, and altered functional
connectivity by functional MRI (Cader et al., 2006).
The mechanisms driving neuronal pathology in MS are of particular
importance, as there appears to be a correlation between cumulative axonal loss
and progressive, irreversible neurological disability (Neumann, 2003; Matthews et
al., 1998; Paolillo et al., 2000; Fisher et al., 2000; Grimaud et al., 1999). As with
demyelination, neuroaxonal damage in MS is a multifactorial process.
We are yet to fully understand the mechanisms driving axonal pathology in
MS. A correlation between demyelination and axonal loss has been demonstrated by
numerous studies. Progressive axonal degeneration and disability was observed in
murine models lacking either myelin associated glycoprotein (MAG) or proteolipid
protein (PLP) (Li et al., 1994; Griffiths et al., 1998). Similar findings were observed
in humans carrying a null mutation in the gene encoding PLP1 (Garbern et al.,
2002). Histopathology of post mortem human MS tissue has shown axonal
transections in lesions of active inflammation (Kornek et al., 2000; Trapp et al.,
1998). Furthermore we know that the establishment and maintenance of axonal
domains is dependent on myelination (Dupree et al., 1999; Dupree et al., 2004;
Marcus et al., 2006; Pomicter et al., 2010).
The hypothesis that axonal damage in MS may occur independently of
demyelination has been suggested by several studies and is a focus of this project.
Axon-specific antibodies have been implicated in axonal degeneration (Zhang et al.,
2005). Axonal damage has also been linked to the presence of reactive resident
microglia, invading inflammatory immune cells, and their toxic metabolites. Release
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of reactive oxygen species, specifically NO, by immune cells has been demonstrated
to directly damage axons and mediate the development of neurological symptoms
(Acar et al., 2003 and Smith, 2005). Studies using post mortem cortical tissue in MS
patients, described axonal abnormalities in areas devoid of demyelination, termed
normal appearing white matter (NAWM) (Siffrin et al., 2010; Ramió-Torrentà et al.,
2006; De Stefano et al., 2003; Davies et al., 2004). The marked reduction of the
neuron-specific marker N-acetyl aspartic acid in MS lesions, and normal appearing
white matter (NAWM) in MS patients suggests that neuronal pathology can occur
early in disease and prior to the formation of overt lesions (Siffrin et al., 2010). MRI
studies on progressive brain atrophy have yet to prove that neuronal damage is
secondary to demyelination (Rudick, et al., 1999; Miller et al., 2002; Narayan et al.,
1997). Siffrin et al., in 2010, showed that cortical demyelination occurred in the late
stages of the disease, and believed it to be a consequence rather than a cause, of
neuronal loss (Siffrin et al., 2010). Thus axonal destabilization and damage has been
shown to occur even in the absence of morphological evidence of demyelination,
however, the mechanisms underlying this process as to how or where this damage
precisely occurs, are still not entirely clear. We believe that investigating the
stability of axonal domains, specifically the axon initial segment, could provide
insight into the mechanisms regulating axonal degeneration and its relationship to
myelination, in multiple sclerosis.
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Background Data:
As more and more studies are establishing that axonal pathology independent of
myelin loss is a viable explanation of the pathogenesis of multiple sclerosis, our lab
decided to investigate the behavior of the axonal domain, the axon initial segment
(AIS), under similar circumstances. To first address this, we employed murine
models of multiple sclerosis.

EAE model:
To evaluate AIS integrity in an inflammatory environment, we utilized the murine
model of chronic experimental autoimmune encephalomyelitis (EAE) as previously
described (DeVries et al., 2012; Secor McVoy et al., 2015; Dupree et al., 2015). EAE
is a murine model, which shares the inflammatory features of MS but none of the
demyelinating aspects. 12 week old mice were injected with a cocktail consisting of
myelin oligodendrocyte protein (MOG), Freund’s adjuvant containing heat-killed M.
tuberculosis and Pertussis toxin (PT). This induced an inflammatory CNS response,
producing clinical symptoms as early as 5 days post-induction. Clinical motor
symptoms were scored daily following immunization and were recorded as follows:
0= no signs, 1.0= limp tail, 2.0= loss of righting reflex, 3.0= paralysis of single hind
limb and 4.0= paralysis of both hind limbs. Mice achieved peak clinical symptoms at
~15 days post induction. Two experimental time points were established: an early
inflammatory time point (3 days post peak clinical symptoms) and a late
inflammatory time point (9 days post peak clinical symptoms). Not all mice achieved
maximum clinical scores by day 10, allowing us to exploit this variation to
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investigate the correlation between disease severity and extent of axonal pathology.
Within each time point, mice were categorized as either EAE 1&2, or EAE 3&4 based
on clinical scoring.

Axon initial segments were shortened following early EAE:
Immunolabeling for markers directed against ankyrinG allowed visualization of
axon initial segments (AIS) in cortical layer V of mice. Quantitative analysis of AIS
numbers and length in layer V or the cortex of EAE mice at the early inflammatory
time point revealed no change in AIS numbers among any of the groups. No change
in AIS length was observed between naïve and early EAE 1&2, however early EAE
3&4 mice showed significantly shortened mean AIS lengths, compared to both the
naïve and EAE 1&2 groups. To determine whether this shortening was an early
event in progressive AIS disruption, or whether the shortening would
spontaneously correct itself with disease progression, we quantified AIS numbers
and lengths at the late inflammatory EAE time point.

Axon initial segments were lost during late EAE:
AIS morphology was assessed following 9 days post peak clinical symptoms (late
EAE). In contrast to the mice at early EAE, quantification of AISs at the late EAE
stage revealed significantly reduced numbers of AIS in both EAE 1&2 and EAE 3&4
groups compared to the naïve mice. As seen in Figure 3 approximately 60% of AISs
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Figure 3. AIS length is reduced in early stages of EAE while the number of AISs
is decreased in the late stages of disease. In Early disease stage (3 days post peak
clinical symptoms), AISs in cortical layer V neurons of naïve (A) and EAE 1&2 (B)
mice were abundant, presented with uniform length and rarely revealed
discontinuous labeling indicative of fragmentation (yellow arrows). In contrast,
AISs of layer V cortical neurons in Early EAE 3&4 mice (C) were frequently reduced
in length (white arrows) and fragmented (yellow arrows). Quantitative analysis
confirmed the immunohistochemical observations. No difference in AIS number
was observed among the Early EAE groups (G). Although no difference in AIS length
was observed between naïve and Early EAE 1&2 mice (H), a significant shortening
was observed with the Early EAE 3&4 mice compared to naïve animals (H). In
contrast, the Late EAE 1&2 mice (E,G) exhibited a significantly reduced in the
number of AISs with a continued progression in AIS loss observed in the Late EAE
3&4 mice (F,G). While there was a significant decrease in AIS length for the Late
EAE 1&2 mice, a significant but less dramatic shortening was observed for the Late
EAE 3&4 mice as compared to the naïve animals (H). Note that with the loss of AISs
(Panel F), punctate AnkG labeling was prevalent. Double labeling for AnkG and the
paranodal marker caspr (see F inset; AnkG – red; caspr – green) revealed that these
pucta were nodes of Ranvier that were not disrupted following EAE induction.
(Asterisks with no associated bracket represent a significant difference from the
naïve group; *p=0.0001, **p=0.008).
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Figure 3
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were lost in the late EAE 1&2 while nearly 75% of AISs were lost in the late EAE 3&4
mice. AIS lengths were measured at the late inflammatory time point as well,
revealing significantly shorter AIS lengths in both EAE 1&2 and EAE 3&4 groups
compared to the naïve mice.
Therefore, we show that the AIS are significantly shortened and the number
significantly reduced in EAE mice. These findings are extremely exciting as they
show a disruption of axonal protein domain organization in the absence
demyelination.

Cuprizone Model:
Demyelination does not disrupt molecular organization of the AIS:
Although MBP labeling detected no demyelination in the cortex of the EAE mice,
subtle, undetected disruptions between the myelin sheath and axon could be
responsible for the loss of AIS protein clustering. To determine whether disrupted
axon-myelin interaction could compromise AIS protein clustering, we analyzed AIS
length and number following demyelination of the cortex using the curizone model.
Exposure of the neurotoxicant, cuprizone (bis-cyclohexanone-oxaldihydrazone), to
young adult C57BL/6 mice induces a synchronous and consistent model for
demyelination followed by remyelination of the 5th layer of the cerebral cortex
(Mason et al., 2001; Matsushima and Morell, 2001; Skripuletz et al., 2008)
6-week-old mice were fed ground chow mixed with cuprizone following a
previously described protocol (Hiremath et al., 1998; Dupree et al., 2004). Treated

26

animals were removed from cuprizone after 3 or 5 weeks for tissue processing and
analysis, while an additional group was maintained on cuprizone for 5 weeks
followed by an additional 3 weeks on normal (non-cuprizone) chow.

Cuprizone induced demyelination does not disrupt AIS structure:
A qualitative assessment of myelin basic protein (MBP) immunolabeling of cortical
layer V, to assess for myelination, revealed reduced MBP levels in mice following 3
weeks of curizone exposure. Following 5 weeks of cuprizone exposure, MBP levels
were further reduced, indicating maximum demyelination. MBP labeling of mice
following the additional 3 weeks of normal chow after 5 weeks cuprizone exposure
revealed an increase in MBP labeling which is consistent with remyelination of
cortical layer V.
Immunolabeling for markers directed against ankyrinG allowed us to
visualize the axon initial segments in cortical layer V of cuprizone mice. Quantitative
analysis of AIS numbers across 3-week-old, 5-week-old cuprizone mice and 5+3
week old cuprizone + normal chow mice revealed no disruption to the organization
of AISs following demyelination. Interestingly, nodes of Ranvier cluster a similar set
of proteins as the AIS, yet following demyelination, these proteins, including Na+
channels and ankyrinG, are no longer clustered in the node of Ranvier. In contrast,
our AIS findings show that following demyelination these proteins maintain their
clustering suggesting that these proteins have differential susceptibility to
pathologic events depending on their location along the axon.
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In summary, our findings demonstrate that the AIS is compromised in EAE, and this
structural disruption is independent of demyelination.
Although these findings are highly intriguing by indicating that axonal pathology
may be independent of myelin loss in an inflammatory environment, these data are
limited to animal models. Here, we will investigate whether similar AIS structural
disruption occurs in human MS tissue.
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Figure 4. AISs are not disrupted following cuprizone-induced demyelination.
Cortical demyelination was assessed by immunolabeling for MBP (A-E). No myelin
loss was detected following 1 week of cuprizone treatment (B). Note a slight
reduction in MBP labeling following 3 weeks of cuprizone exposure (compare A
and C) with a continued decrease in labeling by 5 weeks of treatment (D).
Following an additional 3 weeks without cuprizone, MBP labeling increased
consistent with remyelination (E). Ankyrin-G labeling of cortical layer V axon
initial segments (AIS) revealed no difference among mice that were maintained on
ground chow without cuprizone (F) and mice maintained on cuprizone for 1 week
(G), 3 weeks (H), 5 weeks (I), or 5 weeks with an additional 3 weeks of recovery
(J). Quantitative analysis confirmed that neither AIS number (K) nor AIS length (L)
was altered following cortical demyelination at any exposure time point or as
compared to untreated (naïve) mice.

29

Figure 4

30

MATERIALS AND METHODS

Tissue:
Unfixed cortical samples from multiple sclerosis (MS) and non- multiple sclerosis
(MS) brains were obtained from the Rocky Mountain Multiple Sclerosis Brain Bank
Center. The samples were stored in a freezer at -80°C. The sample information
included patient age, sex, sample type, hours between death and tissue harvest, and
post-mortem pathological evaluation (Table 1). The samples were inspected at VCU
by a neurologist (Unsong Oh, M.D.) and pathologist (Christine Fuller, M.D.) and
samples identified to be gray matter were collected. One 20mm x 15mm x 3mm
specimen of gray matter from each sample was dissected and stored in a 25mm x
20mm x 5mm Tissue-Tek® Cryomold® (Sakura Finetek USA. Torrance, CA) standard,
and frozen in Optimal Cutting Temperature (OCT) compound (Sakura Finetek USA,
Torrance, CA), to be used for immunocytochemistry. Another 20mm x 20mm x 5
mm specimen of gray matter from each sample was collected and processed for
western blot analysis.
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Table 1. Donor information for the Rocky Mountain Multiple Sclerosis Centre brain samples used in this study
Disease
Summary
MS
MS
MS
Control
MS
MS
Control
Control

Sample
Number
299
192
307
352
324
344
486
102

Age
51
81
61
75
66
64
64
21

Gender
M
F
F
F
F
F
M
M

HTTC
3
4.75
2.5
5.5
13.5
65.5

MS

438

75

F

19.5

MS
MS
MS
Control
Control

441
436
448
101
100

61
-

F
-

-

Pathological Evaluation of the Brain
Widespread, chronic, inactive plaques
Extensive, remote, chronic, inactive plaques
Normal cellularity with minimal edema
Widespread and coalescent demyelinative plaques
Well demarcated, chronic plaques with cerebral atrophy
Normal cellularity
Bilateral hemorrhagic infarcts in pareitooccipital regions
Massive periventricular plaque burden with corpus callosum
atrophy
Marked cerebral atrophy with massive plaque burden in
periventricular regions
-

MS = multiple sclerosis; HTTC = hours to tissue collection; - = data not available (NA)
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Immunocytochemistry:
Antibodies:
The mouse monoclonal antibody directed against ankyrinG (ankG) (NeuroMab,
Davis, CA; N106/36; dilution of 1:200), and mouse monoclonal antibody directed
against neurofascin (Nfasc) (NeuroMab, Davis, CA; L11A/41; dilution of 1:1000)
were used to label the axon initial segments. Microglia were labeled with a mouse
monoclonal antibody directed against CD 45 (AbD Serotec, Raleigh, NC; dilution of
1:500), a rabbit polyclonal antibody directed against the ionized calcium binding
adaptor molecule 1 (IBA-1) (Wako Chemicals USA, Richmond, VA; 1:1000), or a
mouse monoclonal antibody human leukocyte antigen DR (HLA DR) (Dako, Ely, UK;
dilution of 1:1000). Myelination of cortical tissue was visualized using a mouse
monoclonal antibody directed against 2',3'-cyclic-nucleotide 3'-phosphodiesterase
(CNP) (Covance, San Diego, CA; SMI 91R, dilution of 1:1000), and mouse monoclonal
antibody directed against myelin basic protein (MBP) (Covance, Chantilly, VA;
dilution of 1:1000). Mouse monoclonal antibody directed against ankyrinG (ankG)
(generous gift from Dr. Manzoor Bhat, University of Texas - San Antonio Health
Science Center) was used for western blotting. All secondary antibodies were
fluorescently tagged with fluorochromes with excitation wavelengths of 405nm,
488nm or 594nm obtained from Invitrogen Life Technologies (Grand Island, NY;
AlexaTM Fluor) and used at a dilution of 1:500.
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Number of Samples:
The number of MS and non-MS samples used for ankyrinG and IBA-1
immunocytochemistry is as follows: MS (n=9), non-MS (n=4). The number of
samples used for CNP immunocytochemistry is as follows: MS (n=4), non-MS (n=4).
The number of samples used for CD45 immunocytochemistry is as follows: MS
(n=9), non-MS (n=3). The number of samples used for MBP immunocytochemistry is
as follows: MS (n=4), non-MS (n=3). The number of samples used for HLA-DR, Nfasc,
and CD 68 immunocytochemistry is as follows: MS (n=2), non-MS (n=2).

Tissue Processing:
Gray matter samples of MS and non-MS tissue were frozen in OCT freezing
compound and placed in a Leica CM 1850 UV cryostat for sectioning. The samples
were placed on the cutting block, with the desired side facing upwards. 40μm
thickness sections (10 sections per sample) were sectioned and mounted on
ProbeOnTM Plus microscope slides (Fisher Scientific, Waltham, MA), one section per
slide. The slides were labeled and stored in a freezer at -80°C.

Immunofluorescent labeling:
Sections were removed from the -80C freezer, and air-dried for 30 minutes to
ensure adhesion to the slide during subsequent steps. Excess OCT was trimmed
from the periphery of the slide and a PAP pen (Daido Sangyo, Tokyo, Japan) was
used to apply a hydrophobic border around the tissue. For labeling with IBA-1, MBP

34

and Nfasc primary antibodies, the slides were immersed in 4% paraformaldehyde
for 1 hour to fix the tissue. Slides were then immersed in -20°C acetone (Fisher
Scientific; Pittsburg, PA) for 10 minutes, washed 3 times in phosphate-buffered
saline (PBS) (0.1 M, pH 7.4; 8g of NaCl + 0.2g of KCl + 1.44g of Na2HPO4 + 0.24g of
KH2PO4) and blocked in a solution of PBS, 0.5% Triton X-100 (MP Biomedicals;
Solon, OH) and 10% cold water fish gelatin (Electron Microscopy Services; Hatfield,
PA) for 15 minutes at room temperature. The blocking solution was slightly
modified for MBP labeling as 1% Triton X-100 was used instead of the routine 0.5%
concentration. Sections were incubated overnight at 4°C in the appropriate primary
antibodies diluted in the blocking solution. One the following day, the sections were
rinsed 3 times in PBS, blocked for 15 minutes at room temperature and incubated in
the appropriate fluorescently labeled secondary antibody, which is dependent on
the host species of the primary antibody. Secondary antibodies were diluted 1:500
in the blocking solution and applied to the sections for 90 minutes. Following the
secondary antibody incubation, sections were rinsed 3 times in PBS, incubated in
BisBenzimide (Sigma-Aldrich, St. Louis, MO, 1:1000 for 2 minutes diluted in PBS) to
label nuclei, rinsed 3 times in PBS and mounted with a coverslip (Fisher Scientific,
Waltham, MA) using the antifade solution VectaShield™ (Vector Laboratories;
Bulingame, CA), and stored at -20°C until imaged. Images not imaged within 1 week
of staining were stored in a freezer at -80°C.
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Confocal Microscopy Imaging:
Samples were first visualized using a Zeiss AxioImager A1 fluorescence microscope
(Carl Zeiss Microscopy, LLC, Thornwood, NY) to ensure that the
immunocytochemistry was effective and to confirm correct orientation of the
sections. All images for qualitative and quantitative analyses were taken with a Zeiss
LSM 710 confocal laser-scanning microscope (Carl Zeiss Microscopy, LLC,
Thornwood, NY). Images were collected and compiled as maximum projection z
stack images consisting of 50 optical images spanning 25μm of tissue. The collection
of 50 images was determined based on Nyquist sampling, 1 Airy disc unit pinhole,
using a 40x oil immersion objective with a numerical aperture of 1.3 Images were
captured at 1908x1908 pixels using a scan average of 2. Each microscopic field
dimension was 215µm x 215µm x 25 μm and each field of view (FOV) collected had
a negligible area without tissue present. Gray matter regions were initially
confirmed based on cell density and pattern of lipofuscin labeling. Non-overlapping
images were taken only from gray matter regions. Between 4-6 images were
collected per section. For 405nm excitation, wavelengths between 440-470 were
collected. For 488nm excitation, wavelengths between 505-530 nm were collected.
For 594nm excitation, wavelengths between 610-650 nm were collected.
Spectral unmixing is a technique used to separate and omit autofluorescent
wavelengths originating from lipofuscin pigment from the fluorescent wavelengths
of interest originating from the antibody tags (Figure 5). Autofluorescence
elimination facilitated quantitative analysis by removing non-specific fluorescence.
Spectral unmixing was performed in real time during image capture. All microscopy
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Figure 5. Spectral unmixing microscopy. Immunocytochemistry image of axon
initial segments labelled with ankG antibody (red lines) and background
autofluorescence emanating from lipofuscin pigment (green), shown prior to
spectral unmixing (A). Channels are then separated by spectral unmixing to
remove unwanted background autofluorescence (C) from the desired image,
visualizing the AIS (B).
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was performed at the Virginia Commonwealth University Department of Anatomy
and Neurobiology Microscopy Facility.

Quantitative Image analysis:
The mouse monoclonal antibody directed against the cytoskeletal scaffolding
protein ankyrinG was used to visualize the axon initial segments (AIS). AIS
quantification was performed by counting the number and measuring the length of
the AIS using the ImageJ software (U. S. National Institutes of Health, Bethesda, MD).
The maximum intensity projection images were opened in ImageJ and the AISs were
manually traced, using the trace tool. Pixels were the units of trace length measured
by ImageJ. As each FOV represented 215µm x 215µm of tissue, and measured 1908
pixels x 1908 pixels, 1µm tissue = 8.9 pixels of the image. Red lines of > 5 µm (i.e. >
45 pixels) were considered AISs and were traced. Punctate labeling of < 5 µm (i.e. <
45 pixels) was considered to be nodes of Ranvier and were not traced, as it has been
shown that nodes of Ranvier are less than 3 µm long (Dupree et al., 1998). The
lengths of the AISs, were logged using the ‘measure’ key. To eliminate AISs that
extended beyond the boundaries of the captured FOV, which would result in an
artificial shortening of the segment, initial segments touching any of the six edges of
the collected z-stack image were excluded from analysis. Data for both AIS length
and number were averaged per sample and a single average for length and for
number was used for statistical analysis. To compare the number of AISs, the data
are represented as a percent of non-MS (% non-MS ± SEM). The data were
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determined to be not normally distributed and thus an unpaired t-test with Welch’s
correction was performed. To compare AIS length, the average length of the AISs in
microns is presented as mean ± SEM. AIS lengths were compared and tabulated in a
length distribution graph. Images collected using other antibodies (Nfasc, CD45,
MBP, CNP, IBA-1, HLA DR, CD 45, CD 68) were saved as maximum intensity
projections and were surveyed and qualitatively assessed using microscopy and
ImageJ. All graphing and statistical analyses were performed using GraphPad Prism
version 6.03 for Windows (GraphPad Software, San Diego, CA USA).

Western Blot Analysis
Tissue processing:
Samples taken for western blot processing were placed in a 30ml Dounce glass
homogenization tube and placed on ice. Lysis buffer (Schafer et al, 2009) (0.32M
sucrose + 5mM sodium phosphate monobasic + 10mM EDTA + 0.1% SDS) and 10
µl/ml of the protease inhibitor cocktail (Sigma-Aldrich; P8340; St. Louis, MO)) was
added and each sample was homogenized using a Glas-Col® motorized metal
handled pestle tissue homogenizer (Glas-Col® Terre Haute, IN) at a motor speed of
60 for ten strokes (1 stroke defined as one full motion of the pestle moving from the
top of the Eppendorf tube, to the bottom and back to the top). The homogenate was
then centrifuged at 600G and 4°C for 10 minutes in a tabletop Eppendorf Centrifuge
5402 (Eppendorf North America, Hauppauge, NY). The supernatants were collected
and stored at -20°C.
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Protein assay:
A protein assay was performed to determine the protein concentrations of the
homogenized samples facilitating equivalent protein loading onto the gel. Bovine
serum albumin (BSA) standards were prepared using serial dilutions of BSA stock
with PBS, as per the Micro BCA Kit protocol (Thermo Scientific, Rockford, IL;
Thermo#23235). 25 µl of BSA standards and 25 µl of 1:10 diluted MS and non-MS
samples were added in triplicates to a 96 well plate. The BCA assay kit reagents A, B
and C were then mixed together in a 25:24:1 ratio and 200 µl of the reagent mix was
added to each of the occupied wells. The well plate was incubated at 37°C and
cooled for 5 minutes before being read in a spectrophotometer. The standard curve
was determined and used to calculate protein concentrations.

Western Blot Protocol:
Protein concentrations across samples were normalized by diluting them with
sample buffer (Lamelli sample buffer: beta-mercaptoethanol, 20:1) to ensure
loading of 20µg of protein per lane. The samples were boiled for 5 minutes, cooled
on ice, centrifuged and vortexed prior to loading the gel (Criterion™ TGX™ 18 well
precast gel 4-15%). 10µl of molecular weight marker (Bio-Rad, Hercules, CA;
Precision Plus Protein™ Kaleidoscope™) was added to the first lane. Western blot
apparatus (Biorad Miniprotean Tetracell; Bio-Rad, Hercules, CA) was filled with
running buffer (0.1 Tris-Glycine + 1g sodium dodecyl sulfate (SDS) and the gels
were run at 70V for 30 minutes to allow the protein to stack, and then at 100V for an
additional 1 hour. The gels were then removed and rocked in cold transfer buffer
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(10x Tris-Glycine:Methanol:DI H2O, 1:2:7) for 15 minutes. A nitrocellulose
membrane was cut to fit the gel and rocked in cold transfer buffer for 15 minutes.
The transfer cassette was made by sandwiching the gel and nitrocellulose
membrane between 2 blotting papers and 2 sponges. The gel was then allowed to
transfer in a gel box on ice at 100V for 2 hours. Following the transfer, the
nitrocellulose membrane was washed in PBS, and incubated in blocking solution
(3% non-fat dry milk:PBST, 1.5g:50ml) for 40 minutes. The membrane was
incubated overnight in the primary antibody (ankyrinG; 1:2500) diluted in the
blocking solution at 4°C. The following day, the membrane was washed in PBS 3
times for 10 minutes each, blocked for 20 minutes, and incubated in a secondary
antibody solution for 1.5 hours. The secondary antibody solution consisted of an
anti-mouse antibody conjugated with horseradish peroxidase (HRP) (1:5000), and
Strep-Tactin HRP conjugate (1:10000). After two 5-minute rinses in phosphate
buffered saline tween (PBST) (50ml of PBS+ 250µl of 10% Tween) and four 10minute PBS rinses, the membrane was incubated in the chemiluminescence reagent
(Millipore Corporation, Billerica, MA; Immobilon Western Chemiluminescent HRP
Substrate) for 5 minutes. The membrane was then transferred to the film cassette
and developed using a Futura 2000 K automatic x-ray film processor (Fisher
industries, Dickinson, ND). The western blot films were qualitatively assessed on an
x-ray viewer and scanned for documentation.
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RESULTS

The axon initial segment (AIS) is the site responsible for action potential initiation
and modulation (Meeks et al., 2007; Rasband, 2010). Alterations in the structure of
this domain result in the disruption of impulse generation (Schafer et al., 2009).
Previous studies from our lab (Clark et al., in review), using the Experimental
Autoimmune Encephalomyelitis (EAE) murine model, which replicates many of the
inflammatory aspects of Multiple Sclerosis (MS) (DeVries et al., 2012; Secor McVoy
et al., 2015; Dupree et al., 2015), demonstrate a reduction in AIS numbers and
length (Clark et al. in review). Interestingly, altered AIS numbers and length
temporally correlate with poorer clinical scores in EAE mice and imply
compromised neuronal function. Although EAE is a model of MS, it is not an exact
replica of the disease (DeVries et al., 2012; Secor McVoy et al., 2015; Dupree et al.,
2015). Therefore to determine whether AIS numbers and AIS lengths are altered in
the human disease, immunocytochemistry was performed on cortical gray matter
samples from both groups. To visualize the AISs, cortical samples were
immunolabeled with the ankyrinG antibody. AnkyrinG is prominent component of
the AIS and is known as the AIS master organizer (He et al., 2013; Kordeli et al.,
1995; Jenkins and Bennett, 2001; Sobotzik et al., 2009; Hedstrom et al., 2008;
Dzhashiashvili et al., 2007; Zhou et al., 1998). Samples were counterstained with the
marker bis benzimide to label the nuclei.
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No difference in cell number was observed between MS and non-MS samples:
Since neuronal pathology is a known component of the MS disease process, we
attempted to evaluate neuronal cell loss in MS and non-MS samples. For this
approach, we employed the neuron specific marker NeuN (Saaltink et al., 2012;
Gómez-Nicola et al., 2013; Smolders et al., 2013). Unfortunately, NeuN did not label
the human tissue. As an alternative approach, we used bis benzimide as an indicator
of cell number. Bis benzimide is not specific to neurons and labels the nucleus of all
cell types. Using this nuclear marker, we quantitatively compared total cell number
between MS and non-MS samples. As shown in Figure 6, no difference in the
number of bis benzimide labeled cells was observed between MS and non-MS
groups. Although not specific to neurons, these counts indicate that cell loss is not
observed in the MS samples.

The number of axon initial segments are not significantly reduced in MS:
To evaluate AIS number in MS and non-MS samples, the number of ankG positive
profiles, greater than 5um, was determined per field of view. As seen in Figure 7,
images from MS and non-MS samples reveal AISs labeling with the ankG antibody.
AIS counts revealed a 40% reduction in the number of AISs between the MS and
non-MS samples. Although quantitation indicated a 40% reduction in AIS number,
statistical analysis indicated that this reduction was not significantly different
(Figure 8). A less stringent statistical analysis, considering each field of view to be an
independent ‘n’ number, revealed a statistically significant reduction of AISs in MS
by 40% (p=.001134) compared to non-MS (Figure 9)
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Figure 6. No difference in cell numbers between MS and non-MS. The number
of nuclei, as stained by bis benzimide, of MS samples as a percentage of non-MS
revealed no difference in the number of cells within MS and non-MS cortex
samples.
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Figure 6
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Figure 7. Sample immunocytochemistry images representative of AIS data.
Immunocytochemistry of Non-MS tissue (panel A) and MS tissue (panel B).
AnkyrinG labelled Axon initial segments (AIS) are shown as red lines (white
arrows). The bis benzimide labelled nuclear regions are shown in blue. The red
blotches are background noise caused by lipofuscin autofluorescence.
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Figure 8. Axon initial segment numbers in multiple sclerosis compared to
non – multiple sclerosis cortical tissue
AIS numbers of MS samples as a percentage of non-MS shows a ~40% reduction
(P value = 0.1934)
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Figure 8
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Figure 9. Axon initial segments in multiple sclerosis compared to nonmultiple sclerosis using each field of view as an individual n number.
AIS numbers of MS samples as a percentage of non-MS shows a ~40% reduction
(P value = 0.001134)
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Figure 9
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Axon initial segment lengths not reduced in multiple sclerosis:
As presented above, the apparent reduction in the number of AISs in MS samples
was not statistically significant; however, changes in AIS length have also been
reported to alter AIS function (Adachi et al., 2014; Grubb and Burrone; Kaphzan et
al., 2011; Kuba et al., 2010,2012). For example, action potential generation
threshold changes with change in length and position of the AIS along the axon. In
addition, our lab has previously reported that AIS length is significantly reduced in
EAE mice and this reduced length preceded AIS loss. Therefore, I proposed that
altered AIS length represents an early pathology of AIS disruption and may present
in MS tissue even in the absence of AIS loss. Therefore, I quantitatively compared
AIS length between MS and non-MS samples. To investigate potential differences in
AIS length between MS and non-MS tissue, we measured the lengths of the ankG
labeled AISs in both groups. Consistent with our EAE work, we analyzed AIS average
length and compared AISs based on groupings. Regardless comparison approach,
statistical analysis revealed no difference in AIS length between MS and non-MS
tissue (Figure 10). As expected, the average AIS length was between 10 and 20 um.

Western Blotting to isolate Axon Initial Segment Protein AnkyrinG:
Our AIS number findings were not significantly different according to statistical
comparison. Although not significantly different, we observed a 40% reduction.
Therefore, we proposed that highly variability among regions may dilute
AIS pathology. Therefore, proposed to further investigate AIS protein integrity by
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western blot analysis. Western blot analysis provides 2 advantages: 1. Since western
blots required homogenized samples, this approach allows a higher throughput
method for analyzing multiple brain samples per donor, and 2. Provides higher
resolution of pathology, as degradative products of AIS proteins would be easy to
visualize even with modest AIS pathology.
Since ankG and its breakdown products have previously been identified by
western blotting and quantified by densitometric analysis (Kordeli et al., 1995;
Schafer et al., 2009; Phillips et al., 2010), we focused out efforts of this protein for
our western blot analysis. As shown in Figure 11, the western blot showed protein
bands at the molecular weights expected to see ankyrinG, at ~480 and ~200 kDA..
Interestingly, these bands were observed in two non-MS samples (n=3), but were
present in only one MS sample (n=4). Bands were found at ~75 kDA as well, where
we would expect to find ankyrinG breakdown products (Schafer et al., 2009; Phillips
et al., 2010).

No correlation between Axon Initial Segment loss in Multiple Sclerosis and
tissue myelination:
Myelin has been shown to play an integral role in the maintenance of the structure
of the Node of Ranvier (Eshed-Eisenbach and Peles, 2013; Susuki et al., 2013;
Dupree et al., 1999). The node of Ranvier and the AIS have a highly similar ion
channel composition and organization (Rasband, 2010; Kole et al., 2008). While this
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Figure 10. Axon Initial Segment lengths comparable between MS and nonMS cortical tissue
Length distribution graph comparing AIS lengths of MS and non-MS tissue. While
the highest number of AIS lengths ranged between 10 – 20 µm, and the lowest
number of AIS lengths were over 30 µm, a comparison across all AIS length
subgroups, revealed no noticeable difference in AIS length between MS and nonMS tissue.

55

Figure 10

56

Figure 11. Western Blot analysis of Ankyrin G in MS and non-MS tissue.
Western blot film labeled with Ankyrin G antibody revealed bands at ~480 kDa
and ~200 kDa molecular weights, where full length isoforms of Ankyrin G are
expected to be seen. Non-MS samples (n=3) revealed two bands while MS samples
revealed only one (n=4). Bands seen at ~75 kDa correspond to potential Ankyrin
G breakdown products
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Figure 11
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would indicate a similar vulnerability of the AIS to the state of myelination of the
neuron, previous studies in our lab (Clark et al., in review) and others (Hamad and
Kole, 2015), using the Cuprizone mouse model of demyelination (Mason et al., 2001;
Matsushima and Morell, 2001; Skripuletz et al., 2008), have demonstrated that the
AIS structure is maintained in demyelinated states. Although studies indicate that
AIS stability is not dependent on myelination in rodents, we determined whether
the state of myelination regulates AIS stability or AIS protein stability in human
tissue. For this study, we employed immunocytochemistry using the cyclic
nucleotide phosphodiesterase (CNP) antibody to label myelin in MS and non-MS
tissue. After selecting 4 MS and 4 non-MS samples that were representative of the
trend seen in our previous AIS quantification analysis, we triple labeled non-MS and
MS tissue samples with CNP (myelin marker), ankyrinG (AIS marker) and
bisbenzimide (nuclear marker), as seen in Figure 12. Qualitative analysis of the
images confirmed our previous findings of an apparent decrease in AIS number in
MS tissue compared to non-MS tissue. Interestingly, although the MS samples
consistently presented fewer AISs, this reduction was independent of the extent of
myelination. As observed in Figure 12, qualitative analysis revealed that the number
of AISs was reduced in demyelinated plaques (Figure 12-C) or in normal appearing
grey matter (Figure 12-B). These findings suggest that the apparent reduction in AIS
number observed in MS does not correlate with the state of cortical myelination.
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Figure 12. No change in AIS numbers between myelinated and demyelinated
MS tissue. Immunocytochemistry of non-MS (A) and MS (B & C) tissue labelled
with CNP antibody (green), a myelin marker, Ankyrin G antibody (red), an AIS
marker, and bis benzimide (blue), a cellular nuclei marker. Non-MS tissue (A)
showed a noticeably higher number of AIS compared to all MS tissue. Myelinated
MS tissue (B) when qualitatively compared with demyelinated MS tissue (C),
showed no observable difference in AIS number, indicating that the lowered AIS
counts were not related to the state of myelination of the tissue. Bis benzimide
staining once again confirmed a consistent number of cells across all tissue
samples.
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DISCUSSION

The goal of this study was to investigate axon initial segment (AIS) pathology in
multiple sclerosis (MS). Data gathered from immunocytochemistry and, to a lesser
extent, western blotting has demonstrated that the proteins clustering in the axon
initial segment may be compromised in multiple sclerosis. Although the number of
AISs was reduced by ~40% in the MS tissue as compared to non-MS tissue, this
apparent reduction was not significantly different based on statistical analysis.
Consistent with the apparent reduction in AIS number, the western blot findings
also suggest a loss of AIS proteins. Quantitation of AIS lengths remained unchanged.
Contrary to what we know about the node of Ranvier’s susceptibility to
demyelination (Dupree et al., 1999; Dupree et al., 2004; Marcus et al., 2006;
Pomicter et al., 2010, Dugandzija-Novaković et al. 1995; Salzer et al., 1997; Rasband
et al., 1998; Rasband et al., 1999; Tait et al., 2000; Bhat et al., 2001), no correlation
between the reduction of AISs and the state of myelination of cortical MS tissue was
observed.

Axon initial segment integrity and Multiple Sclerosis :
Axonal pathology is a hallmark feature of multiple sclerosis, as first described by
Charcot (reviewed by Kornek and Lassmann, 1999). Axonal damage has been
shown to be intimately responsible for many of the characteristic signs and
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symptoms of MS, and is proposed as the cause of the progressive neurological
decline observed in the later stages of the disease (Trapp and Dutta, 2011; Trapp
and Nave, 2008; Haines et al., 2011). Axonal damage, specifically axonal transection,
is abundantly observed in both active and chronic cortical lesions in MS, bearing a
correlation to both inflammation and demyelination (Ferguson et al., 1997; Trapp et
al., 1998). The integrity of axonal domains such as the node of Ranvier (NoR) and
the axon initial segment (AIS) are imperative to maintaining proper axonal
structure and function (Bhat et al, 2001; Buttermore et al., 2013; Chang and
Rasband., 2013). It has been shown by our lab, our collaborators and others that the
NoR is compromised in multiple sclerosis and its models (Bhat et al., 2001; Howell
et al., 2006; Ishibashi et al., 2002; Pillai et al., 2009; Rasband et al., 1999; Rosenbluth
et al., 2003, 2014; Suzuki et al., 2004; Thaxton et al., 2011; Dupree et al., 2004). The
NoR and the AIS also have a highly similar protein, and specifically ion channel
compositions (Buffington and Rasband, 2011), implying a potentially similar
susceptibility of AIS integrity under similar circumstances. Hence, we were
interested in investigating the stability of the AIS in multiple sclerosis.

AIS numbers:
Immunocytochemistry of MS and non-MS tissue, labeled AISs and showed a
dramatic decrease of AISs (>40%) in MS tissue, compared to non-MS tissue. While
these findings are not statistically significant, we think they are of considerable
value, as they follow the trend seen in our background studies using murine models
of MS. There are a variety of reasons why statistical significance was difficult to
63

achieve with this study. It is well known that the use of post mortem human tissue
in biomedical research is challenging due to several methodological problems. The
genetic variability and epigenetic modification of the human genome, make human
tissue much more inconsistent than animal tissue in research (Bennett, 2010). This
is accentuated by other variables such as age, sex, comorbidities, cause of death, and
time till harvest etc., all of which could not be controlled for in this study.
Furthermore, the tissue we had access to for this study was poorly
characterized topographically. Information regarding specific cortical layer, cortical
location and orientation was not available. Additionally, we have determined, via a
post-hoc power of analysis calculation, that the study is underpowered substantially
limiting our ability to observe a significant difference between groups. The power of
analysis calculation revealed that using samples of similar variability, we would
need a total of 68 samples in both MS and non-MS groups to achieve statistical
significance in this study. Unfortunately, additional human samples were not
available at the time of the study. Recently, we have obtained additional samples
from the Netherlands Brain Bank. These samples are well characterized with regard
to age at death, gender, age at disease diagnosis, type of disease, clinical history, post
mortem harvest time and brain cortical region. Preliminary observations from this
new cohort of samples using similar experimental techniques reveals a similar trend
as presented in this study
To strengthen our immunocytochemistry results, we conducted western blot
analyses of human MS and non-MS tissue employing antibodies directed against
ankyrinG. Kordeli et al. (1995) originally found two isoforms of full-length ankyrinG
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in the AIS of human cortical tissue, at 480 and 270 kDA. A study performed by
Schafer et al. (2009) demonstrated that the calcium-dependent cysteine protease,
calpain, mediated AIS breakdown in a stroke model. These authors reported fulllength isoforms of ankyrinG and their breakdown products at ~95 and 72 kDa.
Phillips et al. (2010) while investigating proteolysis in a diffuse brain injury model,
showed full length ankyrinG bands at 212 and 220 kDA with a breakdown product
at 75 kDA. Together these studies provide the feasibility of the western blot
approach to quantify ankyrinG degradation. Our initial experiments to isolate
ankyrinG were inconclusive due to the use of an ankyrinG antibody that was later
found to be ineffective at labeling the protein on western blots. While a working
ankyrinG antibody was eventually acquired, the quantity was insufficient to
effectively optimize the western blot experimental conditions to provide
quantifiable results. However, preliminary findings using the human tissue revealed
protein bands at the molecular weights expected for ankyrinG: 2 bands with
apparent molecular weights of ~480 and ~200 kDA. Furthermore, these bands
were seen in two out of three non-MS samples while only one of four MS samples
revealed full length banding patterns suggesting that loss of ankyrinG in the MS
samples compared to the non-MS samples. Bands were found at ~75 kDA as well,
where we would expect to find ankyrinG breakdown products. While highly
preliminary, these data augment the immunocytochemistry results indicating a
breakdown of ankyrinG in the MS samples.
An important caveat to these findings, however, is that ankyrinG is not
limited to AIS clustering. AnkyrinG also clusters in the node of Ranvier. Therefore, it
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cannot be definitively concluded that ankyrinG breakdown products observed on
the western blots results from AIS breakdown.

AIS lengths:
The AIS is the site of action potential generation and modulation. The AIS is a highly
plastic domain, allowing it to regulate nerve excitability via alterations in its length
and ion channel density (Yoshimura and Rasband, 2014; Kole and Stuart., 2012;
Bender and Trussell, 2012; Kuba., 2012; Ogawa and Rasband., 2008). Previous
studies done by our lab using a mouse model of MS, known as Experimental
Autoimmune Encephalomyelitis (EAE), have demonstrated changes in AIS length in
both acute and chronic disease time points (Clark et at., [in review]). In the EAE
experiments, AIS lengths measured from mice, taken at the early time point (3 days
post peak clinical symptoms) showed significant shortening of AISs in the EAE
tissue, compared to the naive controls, despite no significant reduction in AIS
numbers. However, AIS lengths measured from mice, taken at the late time point (9
days post peak clinical symptoms) showed a much less dramatic shortening of AISs,
despite showing a significant reduction in AIS numbers. One possible explanation
for these findings is that the active inflammatory disease process targets the AIS
structure and shortens it over time, leading to its eventual complete disruption. In
acute inflammation, AIS are undergoing active degradation and shortening, but are
still not lost. As the disease progresses, these AIS are completely lost. We postulate
that there is a subfraction of AISs that are resistant to this inflammatory process,
accounting for the remaining AISs see in the counts. It would follow that the lengths
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of the remaining AISs would be unaltered, by nature of their resistance to
inflammatory disruption.
We were interested in investigating changes in AIS dimensions in human MS tissue,
and performed a quantitative analysis of AIS lengths in MS and non-MS tissue.
Statistical analysis of our data showed no change in AIS length between the two
groups. As we did not see a statistically significant reduction in the number of AISs
between MS and non-MS tissue, we would not expect to see a significant change in
AIS lengths between the two groups. Another possible explanation for the lack of
alteration to AIS lengths despite seeing a dramatic reduction of AIS numbers in MS
samples is that the remaining AISs found in the MS tissue are resistant to disruption
by pathological processes. This is especially accurate since post mortem human
samples bear a higher resemblance to late stage EAE than to early stage EAE, when
comparing pathogenesis timelines. While the mechanisms surrounding AIS
disruption and shortening in these scenarios are not fully understood, we believe
that our findings with the human tissue and murine EAE studies warrant further
investigation in this area.

AIS integrity is not related to demyelination:
The myelin sheath, produced by the oligodendrocytes in the CNS, envelops the axon
and plays a vital role in neuronal functioning. Disruption of the myelin sheath
results in disruption of axonal integrity. It has been shown by our lab (Dupree et al.,
1999; Dupree et al., 2004; Marcus et al., 2006; Pomicter et al., 2010), and others
(Kuba and Susuki., 2015; Rasband and Chang., 2013; Rasband et al., 1999; Tait et al.,
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2000; Bhat et al., 2001), that the establishment and maintenance of the node of
Ranvier is highly dependent on the presence of myelin. However, despite the
compositional and structural similarities between the NoR and the AIS, studies
show that the establishment of the AIS is not dependent on myelin (Kuba and
Susuki., 2015; Rasband and Chang., 2013; Buttermore et al., 2013). Previous studies
done in our lab using the Cuprizone model (a demyelinating/remyelinating murine
model) have shown no change in AIS integrity in demyelinated mouse cortical tissue
(Clark et al., [in review]). Furthermore, studies performed by our lab using the EAE
model (a murine model exhibiting cortical inflammation absent any cortical
demyelination), showed that AISs are lost in myelinated cortical tissue. These
findings imply that the AIS structure is not dependent on myelin (Clark et al., [in
review]).
To determine if this trend is observed in human multiple sclerosis, we
attempted to investigate the relationship between AISs and myelin in human MS
tissue. Initial attempts to immunolabel the tissue using the antibodies directed
against Myelin Basic Protein (MBP) and Myelin Oligodendrocyte Glycoprotein
(MOG) were unsuccessful, showing little to no specific staining, as the human tissue
in our possession was unfixed, and the antibodies required fixed tissue to effectively
label myelin. Post-fixing the tissue yielded no discernable change in the
effectiveness of the immunolabelling. Experiments using the antibody 2',3'-cyclicnucleotide 3'-phosphodiesterase (CNP) resulted in successful labeling of myelin in
the unfixed human tissue. Qualitative analysis of the MS and non-MS human tissue
showed similar regions of myelination and demyelination across all samples.
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Consistent with the idea that AIS disruption is independent of myelin loss, Figure 12
reveals comparable myelin labeling in the MS and non-MS samples while the
number of AISs is substantially reduced in the MS samples compared to the non-MS
samples. This suggests that AIS loss occurred in the absence of demyelination.
Multiple sclerosis, has for decades, been considered a primarily a demyelinating and
inflammatory disease, with subsequent axonal pathology. These findings, correlate
with our background studies, and are extremely exciting as they suggest that axonal
pathology is a primary event in MS, showing a disruption in axonal protein domain
organization, independent of demyelination.

In conclusion, while we did not show a statistically significant reduction of axon
initial segments in multiple sclerosis, our results highlight a trend, which
demonstrates the AISs may be disrupted in MS. We show that axonal pathology is a
primary event in MS, as AIS integrity is not related to demyelination. These findings,
while preliminary, are highly exciting as they enhance our understanding of what
was once considered a prototype demyelinating disease.
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